Latest News

Azerbaijan: TotalEnergies Announces Final Investment Decision for Absheron Full Field Development

YYForce 发布 2026 年上半年财务业绩，营收同比增长 26.8% 至 3,270 万美元

Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva

Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP)

Mirum Pharmaceuticals et Incyte annoncent l’autorisation par la FDA américaine d’Atebrioz™ (zilurgisertib) pour les patients adultes et pédiatriques atteints de fibrodysplasie ossifiante progressive

Mirum Pharmaceuticals und Incyte melden FDA-Zulassung für Atebrioz™ (Zilurgisertib) für erwachsene und pädiatrische Patienten mit Fibrodysplasia ossificans progressiva

Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages York Space Systems Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YSS

Did Zeta Global Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?